Free Medical Research Findings is Just a Click Away, Thanks to Oncotarget

Oncotarget is a free to access online medical journal that is published weekly by Impact Journals. The weekly issue can be availed in hard copy following special requests. The journal was founded in 2010 after the founders realized a gap in the way scientific research findings were reaching the people. Oncotarget was created on a mission of availing scientific results timely and to a wider group of people.

Achievements

Oncotarget is led by top scientists with remarkable hands-on experience. Mikhail Blagosklonny, a well-known scientist and former oncology professor and Andrei V. Gudkov, a cancer researcher and college professor are the journal’s editors-in-chief. The papers published in the journal are peer-reviewed, leaving no room for mistakes. The review also ensures that the scientific results leave the impact that they were intended to. Oncotarget hopes to one day achieve a life without diseases. Though the journey is long, so much more like fighting diseases through the use of basic clinical science has been accomplished. The researchers have also had an opportunity to play a part in the growth of science. The journal endeavors to unite the different fields of sciences by eliminating the divides between them.

Going Beyond Oncology

Initially, Oncotarget was focused on the treatments and therapies of cancer with the aim of improving the lives of cancer patients. The research conducted was directed at establishing the basis of the cancer therapies in the market and those in the pipeline. Over the years and after marking tremendous success, Oncotarget diversified the coverage to include other areas of science. Currently, the journal accepts papers on Pathology, Immunology, Neurotarget, Microbiology Autophagy, Cell Death, Circadian Rhythm, and neuroscience. By including other fields of science, Oncotarget has created a one-stop shop for people needing medical information on different ailments.

Accolades

Oncotarget has enjoyed great reception by the people who use the information contained in the journal. Consequently, many lives have been improved. The remarkable work at the firm received many praises and accolades. In 2013, some of the members at Oncotarget were awarded the Breakthrough Prize, an award that is considered to be a top honor. The members were Michael N. Hall, Bert Vogelstein, Alexander Varshavsky, and Stephen J. Elledge.

The Contributions Of Clay Siegall In Cancer Research and Therapy.

Clay Siegall is a Seattle-based leading innovator in the field of biotechnology and cancer-related therapies. He currently serves on the board of Seattle Genetics, as well as serving as the firm’s CEO and President. He co-founded the firm in 1998 with the goal of providing scientific innovation centered on assisting cancer patients through meticulous drug development and research practices.

From his education and training at the University of Maryland, Clay Siegall received a B.S degree in Zoology before proceeding to the George Washington University where he earned a Ph.D. in Genetics.

Before the establishment of Seattle Genetics, he had served at the National Cancer Institute as Biotechnology Fellow and Staff Fellow. Dr. Siegall embarked on his career in research at the Bristol-Myers Squibb Pharmaceutical Research Institute, working as a Senior Research Investigator, and later on as a Principal Scientist.

Clay Siegall has over 20 years of cancer research under his belt. Throughout his career, he has had an unwavering commitment to alleviating the pain and suffering experienced by cancer patients and improving their general quality of life. He is guided by a constant need to create and implement innovative research breakthroughs in cancer therapies.

Under the guidance of Dr. Siegall, Seattle Genetics was one of the first companies to develop an antibody drug conjugate (ADC), known as ADCETRIS, in partnership with Takeda Pharmaceutical Company. The drug received FDA approval in 2011 and is currently available to cancer patients in over 65 countries globally. The expanding global impact of ADCETRIS is proof of Clay Siegall’s commitment to fast-tracking cancer therapies in the medical community.

He has also overseen strategic partnerships for its ADCs with more than twenty collaborative programs with firms such as AbbVie, Genentech, GlaxoSmithKline, and Pfizer. Such partnerships ensure the use of its leading ADC technology in both preclinical and clinical drug developments.

Dr. Siegall’s visionary leadership has enabled him to raise more than $1.2 billion in capital for Seattle Genetics. This includes both private and public investors, as well as the firm’s IPO in 2001. This investment influx has contributed to the growth and development of the firm, with its stock value tripling in the stretch of 5 years.

Clay Siegall has over 15 patents and has currently published over 70 research articles. He also serves on the panels of Alder BioPharmaceuticals, Ultragenyx Pharmaceutical, and the Washington Roundtable.

In 2013, he received the University of Maryland Alumnus of the Year award for Computer, Math, and Natural Sciences.